Merus N.V. (NASDAQ:MRUS) COO Peter B. Silverman Sells 25,000 Shares

Merus N.V. (NASDAQ:MRUS - Get Free Report) COO Peter B. Silverman sold 25,000 shares of the business's stock in a transaction dated Thursday, July 17th. The shares were sold at an average price of $60.00, for a total transaction of $1,500,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Peter B. Silverman also recently made the following trade(s):

• On Wednesday, July 9th, Peter B. Silverman sold 6,695 shares of Merus stock. The shares were sold at an average price of $55.00, for a total transaction of $368,225.00.
• On Thursday, July 10th, Peter B. Silverman sold 16,805 shares of Merus stock. The shares were sold at an average price of $55.00, for a total transaction of $924,275.00.
• On Friday, June 20th, Peter B. Silverman sold 34,000 shares of Merus stock. The shares were sold at an average price of $52.76, for a total transaction of $1,793,840.00.

Merus Trading Up 3.0%

Shares of NASDAQ MRUS traded up $1.82 during midday trading on Friday, reaching $63.26. The company's stock had a trading volume of 1,061,470 shares, compared to its average volume of 733,967. The stock has a market capitalization of $4.38 billion, a price-to-earnings ratio of -15.50 and a beta of 1.00. Merus N.V. has a fifty-two week low of $33.19 and a fifty-two week high of $63.43. The stock has a 50 day simple moving average of $52.47 and a 200-day simple moving average of $46.20.

Merus (NASDAQ:MRUS - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($1.40) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). Merus had a negative return on equity of 35.99% and a negative net margin of 506.73%. The company had revenue of $26.49 million for the quarter, compared to the consensus estimate of $7.82 million. As a group, equities analysts anticipate that Merus N.V. will post -3.85 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on MRUS shares. Guggenheim reaffirmed a "buy" rating and set a $109.00 price objective on shares of Merus in a report on Friday, March 28th. Wells Fargo & Company reduced their price target on shares of Merus from $91.00 to $89.00 and set an "overweight" rating for the company in a report on Thursday, May 8th. Needham & Company LLC reissued a "buy" rating and issued a $75.00 price target on shares of Merus in a report on Monday, May 19th. William Blair reissued an "outperform" rating on shares of Merus in a report on Monday, April 28th. Finally, BMO Capital Markets set a $110.00 price target on shares of Merus and gave the company an "outperform" rating in a report on Friday, May 23rd. One equities research analyst has rated the stock with a sell rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $84.64.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC lifted its holdings in shares of Merus by 2,153.6% in the 1st quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 603 shares in the last quarter. State of Wyoming bought a new position in shares of Merus during the 4th quarter worth $48,000. Wells Fargo & Company MN boosted its stake in Merus by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 300 shares during the period. GF Fund Management CO. LTD. bought a new position in Merus in the 4th quarter worth about $60,000. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of Merus by 955.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,794 shares of the biotechnology company's stock valued at $76,000 after acquiring an additional 1,624 shares during the last quarter. Institutional investors and hedge funds own 96.14% of the company's stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.